ANTIGORPUTZ-FARMAKO KONJUGATUAK (ADC): minbiziaren aurkako terapien etorkizuna?

Abstract

ABSTRACT: Antibody Drug Conjugates (ADC) are monoclonal antibodies (mAb) associated with a cytotoxic drug by a chemical covalent linker. These ADC achieve precise and effective elimination of cancer cells by combining the potent lethal effect of the drug with the specificity of the antibody. The effective design of ADCs against cancer requires the selection of a suitable target recognized by the monoclonal antibody, the use of potent cytotoxic effector molecules and conjugation methods between the drug and the antibody that ensure high stability in blood and efficient intracellular release. Advances in these aspects have resulted in the approval of 13 ADC by the FDA, with over 140 candidates in different clinical stages. These new cancer drugs are leading a new era of targeted therapy. In this work we review the molecular aspects of the ADC components, their mechanism of action and how these factors influence their activity. The approved ADC are also reviewed, as well as the current and future challenges for the development of the next generations of ADC.